All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...

US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...

Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T ...

In a report released on March 7, Stephen Barker from Jefferies maintained a Buy rating on Kyowa Kirin Co (KYKOF – Research Report), with a ...

Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Japanese drugmaker Kyowa Kirin and Swiss generics and biosimilars giant Sandoz have won approval for the partial change of their rituximab biosimilar for the treatment of refractory nephrotic syndrome ...

PRINCETON, N.J., Feb. 26, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy ...

Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

The agreement with SNS follows similar arrangements made with reimbursement authorities in the United Kingdom (UK), Ireland, ...

X-linked hypophosphataemia (XLH) is a rare, hereditary and lifelong renal phosphate wasting disorder caused by mutations in ...